Vir Biotechnology, Inc. (VIR) Latest Company News

Oct 14, 2026, 16:58 UTC
Vir Biotechnology, Inc. and GILEAD SCIENCES, INC. announced a collaboration to create three T-cell engagers for treating solid tumors.
Source:
- benzinga.com
- zacks.com
Oct 14, 2026, 12:42 UTC
Vir Biotechnology entered into a stock purchase agreement to issue 1,765,486 shares of common stock to Gilead Sciences for $14.16 per share, or $25 million in total.
Oct 5, 2026, 20:05 UTC
Vir Biotechnology announced it will present expanded Phase 2 SOLSTICE trial data for elebsiran and tobevibart in chronic hepatitis delta at AASLD's The Liver Meeting 2026 in Denver, Colorado, November 5-9, 2026.
Source:
- businesswire.com
Oct 1, 2026, 12:35 UTC
Vir Biotechnology, Inc. changed Brent Sabatini's role to Senior Vice President and Chief Accounting Officer, effective October 5, 2026.
Oct 1, 2026, 12:35 UTC
Vir Biotechnology, Inc. appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026.
Aug 13, 2026, 00:00 UTC
Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.
Aug 6, 2026, 01:36 UTC
Vir Biotechnology, Inc. reported Q2 2026 earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share, compared to a loss of $0.80 per share a year ago.
Source:
Jul 24, 2026, 12:30 UTC
Vir Biotechnology announced that Brent Sabatini was appointed Interim Principal Financial Officer, effective July 23, and that Jason O'Byrne is leaving the company to pursue another opportunity, remaining through August 3 for a smooth transition.
Source:
- businesswire.com

VIR

Vir Biotechnology, Inc. and GILEAD SCIENCES, INC. announced a collaboration to create three T-cell engagers for treating solid tumors.

Vir Biotechnology entered into a stock purchase agreement to issue 1,765,486 shares of common stock to Gilead Sciences for $14.16 per share, or $25 million in total.

Vir Biotechnology announced it will present expanded Phase 2 SOLSTICE trial data for elebsiran and tobevibart in chronic hepatitis delta at AASLD's The Liver Meeting 2026 in Denver, Colorado, November 5-9, 2026.

Vir Biotechnology, Inc. changed Brent Sabatini's role to Senior Vice President and Chief Accounting Officer, effective October 5, 2026.

Vir Biotechnology, Inc. appointed Aziz Sawaf as Executive Vice President and Chief Financial Officer, effective October 5, 2026.

Olema Pharmaceuticals appointed Jason O'Byrne as Chief Financial Officer, principal financial officer and principal accounting officer, effective as of the announcement date.

Vir Biotechnology, Inc. reported Q2 2026 earnings of $0.47 per share, missing the Zacks Consensus Estimate of $0.83 per share, compared to a loss of $0.80 per share a year ago.

Vir Biotechnology announced that Brent Sabatini was appointed Interim Principal Financial Officer, effective July 23, and that Jason O'Byrne is leaving the company to pursue another opportunity, remaining through August 3 for a smooth transition.